Foresee Pharmaceuticals Co. Ltd

Detailed Description

Foresee Pharmaceuticals Co., Ltd., clinical-stage pharmaceutical company, engages in the development and commercialization of drugs in Taiwan and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; FP-015, for the treatment of neurological diseases; and FP-002 for the treatment of acromegaly, as well as FP-008 for the treatment of diabetic retinopathy. Its new chemical entity pipeline products consists of FP-020 to treat alport syndrome; FP-025, a selective matrix metalloproteinase-12 inhibitor, which is in Phase II clinical trial for the treatment of asthama, chronic obstructive pulmonary diseases, and emphysema or sarcoidosis; and FP-045, a small molecule mitochondrial aldehyde dehydrogenase 2 that completed Phase I clinical study for the treatment of peripheral arterial disease, fanconi anemia, and cardiorenal metabolic diseases. The company's strategic partners include Pierre Fabre Medicament Production and ScinoPharm. Foresee Pharmaceuticals Co., Ltd. was founded in 2013 and is headquartered in Taipei, Taiwan.